{"id":"NCT03829241","sponsor":"Biohaven Pharmaceuticals, Inc.","briefTitle":"Randomized Trial of Adult Participants With Generalized Anxiety Disorder","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of Troriluzole in Generalized Anxiety Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-02-19","primaryCompletion":"2020-01-14","completion":"2020-05-08","firstPosted":"2019-02-04","resultsPosted":"2022-12-28","lastUpdate":"2024-05-08"},"enrollment":881,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Generalized Anxiety Disorder"],"interventions":[{"type":"DRUG","name":"Troriluzole","otherNames":["BHV-4157"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Troriluzole","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy of troriluzole versus placebo in participants with generalized anxiety disorder.","primaryOutcome":{"measure":"Change From Baseline in the HAM-A Total Score at Week 8","timeFrame":"Baseline, Week 8","effectByArm":[{"arm":"Troriluzole","deltaMin":-9.28,"sd":null},{"arm":"Placebo","deltaMin":-9.35,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.917"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":9},"locations":{"siteCount":53,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":199},"commonTop":["Nausea","Upper respiratory tract infection","Nasopharyngitis","Headache","Fatigue"]}}